The two major signaling cascades of glycoprotein 130 (gp130) receptor, SHP2/ERK and STAT pathways play an important role in cardiac development, hypertrophy, protection and remodeling. Experimental data suggest that signaling of gp130 is beneficial for the growth and survival of cardiomyocytes. The level of gp130 protein in serum is a prognostic indicator of morbidity and mortality in patients with heart failure or myocardial infarction. Creative BioMart Biomarker is capable to provide our customers with superior gp130 detection service, various detection methods ensuring high sensitivity for detecting biomarkers in different samples with different concentrations.
Introduction
Interleukin-6 (IL-6)-type cytokine binds to the α-subunit of its transmembrane receptor, induces homodimerization of the gp130 receptor, or gp130 heterodimerization of either of the leukemia inhibitory factor (LIF) and oncostatin M (OSM) receptor β-subunits. After dimerization of the gp130 receptor complex, Janus kinase-1/2 (JAK1/2), which is linked to the proximal region of the intracytoplasmic membrane of the receptor subunit, is catalytically activated, and self- transphosphorylases tyrosine residues occurs in the intracellular region of the gp130 receptor. Subsequently, two major intracellular signaling cascades are triggered, the SHP2/ERK pathway and the STAT pathway. Activation of SHP2 further activates the Akt pathway and enhances MEK/ERK signal by binding to the growth factor receptor binding protein 2 (Grb2)-associated binding protein 1/2 (Gab1/2) and phosphatidylinositol 3 kinase (PI3K). gp130-mediated signal activation plays an important role in stem cell and cardiomyogenesis. In the adult heart, it is involved in many physiological and pathophysiological processes.
Figure 1. Role of gp130 downstream signalling in the heart. (Fischer, P. 2008)
The ligands LIF and CT-1 of gp130 are highly expressed during cardiomyogenesis and promote the proliferation and survival of embryonic cardiomyocytes, suggesting that the gp130 receptor system may play an important role in cardiac development by regulating cardiomyogenesis, cardiomyocyte survival and growth. In experimental models, gp130 receptor signaling is critical for cardiac development and for cardioprotection against physiological and pathophysiological stress. The beneficial effects of gp130 require a balance between STAT and ERK signaling pathways, and the negative feedback mechanism, the SOCS protein, plays an important role. Failure of negative feedback signals can lead to loss of cardiomyocytes, maladaptive hypertrophy and cardiac dysfunction. Attenuated STAT3 activation and decreased SOCS3 expression were observed in patients with end-stage heart failure, reflecting a disorder in the physiological activity of the gp130 signaling system. Balanced gp130 signaling appears to have cardioprotective effects, while unbalanced gp130 signaling further leads to maladaptation and heart failure.
Application of gp130
Serum levels of gp130, can be used as a prognostic indicator of morbidity and mortality in patients with heart failure or myocardial infarction.
Our Advantages
- Accept a wide range of sample types
- Provide multiple detection methods
- Ensure high sensitivity for detecting gp130 in different samples
- Ensure high accuracy and repeatable gp130 detection
- Ensure a wide kinetic range to detect samples of different concentrations
- Short experimental period
Workflow of gp130 Detection at Creative BioMart Biomarker
Creative BioMart Biomarker strictly controls each specific experimental step in the gp130 detection procedure to ensure high sensitivity, high accuracy and repeatable gp130 detection.
Please feel free to contact us if you would like to know more about gp130 detection. At Creative BioMart Biomarker, we not only provide high-quality gp130 detection service, but also provide detection services for other biomarkers. Additionally, our experts can also provide and help design the best solution according to your specific requirements.
Reference:
- Fischer, P.; Hilfiker-Kleiner, D. Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects. Br J Pharmacol. 2008, 153(Suppl 1): S414–S427.
